Drug Information

Drug General Information
Drug ID
D06LOQ
Former ID
DNC007422
Drug Name
ARZOXIFENE
Drug Type
Small molecular drug
Indication Breast cancer [ICD9: 174, 175; ICD10:C50] Approved [521695], [549961]
Structure
Download
2D MOL

3D MOL
Formula
C28H29NO4S
Canonical SMILES
COC1=CC=C(C=C1)C2=C(C3=C(S2)C=C(C=C3)O)OC4=CC=C(C=C4)OC<br />CN5CCCCC5
InChI
1S/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3
InChIKey
MCGDSOGUHLTADD-UHFFFAOYSA-N
PubChem Compound ID
179337
Target and Pathway
Target(s) Estrogen receptor Target Info Inhibitor [528827]
Estrogen receptor beta Target Info Inhibitor [528827]
KEGG Pathway Estrogen signaling pathway
Prolactin signaling pathway
Thyroid hormone signaling pathway
Endocrine and other factor-regulated calcium reabsorption
Proteoglycans in cancerhsa04915:Estrogen signaling pathway
NetPath Pathway FSH Signaling Pathway
EGFR1 Signaling Pathway
RANKL Signaling Pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling
Signaling events mediated by HDAC Class II
Plasma membrane estrogen receptor signaling
LKB1 signaling events
Regulation of Telomerase
ATF-2 transcription factor network
AP-1 transcription factor network
FOXM1 transcription factor network
Validated nuclear estrogen receptor alpha network
Signaling mediated by p38-alpha and p38-beta
FOXA1 transcription factor networker_nongenomic_pathway:Plasma membrane estrogen receptor signaling
Validated nuclear estrogen receptor beta network
Reactome Nuclear signaling by ERBB4
Nuclear Receptor transcription pathwayR-HSA-383280:Nuclear Receptor transcription pathway
WikiPathways Estrogen signaling pathway
Nuclear Receptors Meta-Pathway
Estrogen Receptor Pathway
Signaling by ERBB4
JAK/STAT
Integrated Pancreatic Cancer Pathway
Leptin signaling pathway
miR-targeted genes in muscle cell - TarBase
Integrated Breast Cancer Pathway
Nuclear ReceptorsWP706:SIDS Susceptibility Pathways
Ovarian Infertility Genes
Nuclear Receptors
References
Ref 521695ClinicalTrials.gov (NCT00190697) A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment. U.S. National Institutes of Health.
Ref 549961Clinical pipeline report, company report or official report of Lilly.
Ref 528827J Med Chem. 2007 May 31;50(11):2682-92. Epub 2007 May 10.Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.